Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | SCD | O00767 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095321 | 0.96 | CYP3A4 (0.35) | RAF1BRAFCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4103892 | 0.93 | GPBAR1 (0.35) | SCDGPBAR1 | |
| SCHEMBL4096264 | 0.93 | GPBAR1 (0.33) | SCDGPBAR1 | |
| SCHEMBL4102190 | 0.93 | GPBAR1 (0.33) | SCDGPBAR1 | |
| SCHEMBL4106287 | 0.86 | SMN1; SMN2 (0.35) | CYP3A4CYP2C19GPBAR1 | |
| SCHEMBL4091444 | 0.86 | TRPA1 (0.40) | GPBAR1 | |
| SCHEMBL4096874 | 0.86 | TRPA1 (0.35) | — | |
| SCHEMBL4090336 | 0.85 | TRPA1 (0.38) | CYP3A4CYP2C19 | |
| SCHEMBL4090274 | 0.85 | TRPA1 (0.37) | GPBAR1 | |
| SCHEMBL4098189 | 0.85 | CYP3A4 (0.34) | RAF1CYP3A4CYP2D6CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | RAF1 821/4885BRAF 845/4885SCD 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.